Faces of Discovery: Chaska Walton, PhD, Pioneers Living Therapies for Alzheimer’s Disease
The Buck Institute’s commitment to advancing human health is exemplified by the groundbreaking work of its scientists. Through its "Faces of Discovery" series, the institute shines a spotlight on the brilliant minds dedicated to unraveling the complexities of aging and pioneering innovative treatments. This installment delves into the remarkable research of Dr. Chaska Walton, a research scientist in Julie Andersen’s lab, whose visionary work on developing smart delivery systems for Alzheimer’s disease has garnered significant national recognition. Dr. Walton’s approach, funded by a prestigious $2.4 million NIH Transformative Research Award – one of only nine awarded nationwide – represents a paradigm shift in how we conceptualize and treat neurodegenerative disorders. This in-depth exploration, the second part of a two-part interview, moves beyond the initial motivations and necessity for novel Alzheimer’s treatments, offering a detailed look into Dr. Walton’s laboratory innovations and projections for the future of the field.
Dr. Walton’s academic journey is a testament to a persistent curiosity about the human brain, a curiosity that has propelled them across continents and disciplines. Their path began with studies in psychology and neuroscience at the Autonomous University of Barcelona, laying a foundational understanding of neural function. This was followed by doctoral work at the esteemed Cajal Institute in Madrid. It was during this period that Dr. Walton challenged a deeply entrenched scientific dogma: the idea that mature neurons, once thought to be terminally differentiated, could re-enter the cell cycle. This groundbreaking discovery, partly inspired by the forward-thinking visions of Santiago Ramón y Cajal himself, who posited that future science might overturn even his most definitive pronouncements, opened new avenues for understanding neuronal plasticity and repair. This spirit of radical reimagining of biological processes has been a driving force in Dr. Walton’s subsequent career at the Buck Institute. Here, their focus has evolved from investigating the mechanisms of neuronal vulnerability and aging to engineering sophisticated synthetic immune-cell therapies for Alzheimer’s disease. This includes the development of programmable CAR-Treg cells and advanced smart cell delivery platforms. Dr. Walton’s research is firmly rooted in the belief that neurodegeneration is not an immutable consequence of aging but a dynamic biological process amenable to interrogation, engineering, and ultimately, fundamental change. This interdisciplinary approach sits at the crucial intersection of neuroscience, synthetic biology, and translational medicine, embodying a philosophy where innovation thrives without rigid constraints.
Engineering Cellular Physicians: A Breakthrough in Alzheimer’s Treatment
One of the most striking recent advancements in Dr. Walton’s lab involves the innovative concept of genetically modifying living cells to act as miniature therapeutic agents. "A particularly remarkable breakthrough was realizing that we can genetically modify cells to detect amyloid beta senile plaques and, in response, produce and secrete the FDA-approved amyloid beta-clearing antibody Leqembi," Dr. Walton explains. This capability transforms cells into highly specialized, proactive medical responders.
The implications of this are profound. Dr. Walton elaborates, "This means cells can be engineered to act as mini physicians. We are shrinking your doctor to about 20 nanometers and giving them superpowers." The inherent advantage of this cellular approach lies in its unparalleled ability for early detection and precise intervention. Unlike human physicians who rely on symptomatic presentation, which often signifies disease progression over extended periods, engineered cells can continuously monitor the biological landscape at a microscopic level. "A physician will never be able to detect pathology as early as a cell can, because cells continuously scrutinize the body at the microscopic level. Your doctor has to wait until you are sick, by which time the disease has evolved for days, weeks, months, or even years, depending on the pathology." Furthermore, the precision of cellular delivery far surpasses conventional drug administration. "A physician will never be able to deliver a drug directly to a single cell, a level of precision that engineered cells achieve with ease." This fundamental shift in therapeutic delivery heralds a new era of medicine. "In a future where cells are the physicians, we will rethink the limits of medicine. We are taking the first steps toward that future."
Explaining Complex Science to a Wider Audience
To convey the essence of this cutting-edge research to a lay audience, Dr. Walton uses an analogy that resonates with everyday experience. "We work on teaching living cells to act like tiny doctors inside the body," they explain, simplifying the complex scientific principles. The traditional model of healthcare, where patients seek human doctors after symptoms manifest and medicines are distributed systemically, is contrasted with this novel approach. "Normally, when we get sick, we rely on human doctors to detect disease and give us medicine. But doctors can only act once symptoms appear, and medicines spread throughout the body even where they are not needed."
Dr. Walton’s research aims to reprogram specific immune cells to become vigilant disease detectors, initiating therapeutic action precisely where and when it is needed. "My research is about engineering certain immune cells so they can recognize very early signs of diseases like Alzheimer’s and release medicine exactly where it is needed and only when it is needed." A critical aspect of many complex diseases, including Alzheimer’s, is their multifactorial nature, involving several interconnected problems. Current medical interventions often address these issues in isolation. However, the engineered cells developed by Dr. Walton’s team can be programmed to deliver a combination of therapies simultaneously, offering a more comprehensive and potent treatment strategy. "Another important part is that many complex diseases are not caused by just one problem. They are more like several problems happening at once. Current medicine usually treats only one of those problems at a time. The cells we engineer can be programmed to deliver multiple medicines together, like a combination treatment, so they can tackle several aspects of a disease at the same time." This innovative approach can be conceptualized as deploying an internal repair crew that continuously monitors the body, addresses issues at their source, and ceases activity once the repair is complete. The ultimate goal is to achieve earlier disease detection, more precise treatment, and to transform currently incurable conditions into manageable or treatable ones.
The Future of Everyday Health: Proactive, Internalized Medicine
The potential impact of Dr. Walton’s research on everyday life and health is transformative. The traditional paradigm of reactive healthcare, where medical interventions occur after symptoms appear and drugs are administered systemically, is poised for a radical overhaul. Dr. Walton envisions a future where a "secondary immune system" resides within the body for life. This engineered system, akin to our natural immune defenses, would continuously patrol the body, identify early signs of disease long before any symptoms emerge, and deliver therapeutic agents with pinpoint accuracy. "This approach to medicine will dramatically change what everyday health looks like," Dr. Walton states. "Today, we rely on physicians to detect disease after symptoms appear and to prescribe drugs that circulate through the whole body. In the future, we envision a secondary immune system that lives inside us for life."
A key aspect of this future is the body’s inherent capacity to produce its own medicines. Instead of recurrent reliance on expensive medications, infusions, or injections, therapeutic molecules would be generated on-demand within the body, precisely at the site of pathology and only for the duration necessary. "The body itself will manufacture many of the drugs it needs. Instead of repeatedly buying expensive medications and receiving infusions or injections, therapeutic molecules will be produced on demand inside the body, exactly at the site of disease and only for as long as required. Treatment becomes a built-in function of the body rather than an external product." This shift promises to significantly reduce the need for conventional medical interventions. The necessity for frequent hospital visits, diagnostic imaging, blood tests, and repeated drug administrations for chronic illness management could diminish substantially. Furthermore, the systemic side effects associated with widespread drug distribution would be eliminated as treatments are localized and precisely delivered. "As a result, many of the things physicians and hospitals do today will no longer be needed. Instead of diagnosing disease late and reacting to accumulated damage, medicine will become proactive and continuous. People will not need to visit hospitals nearly as often, nor rely on frequent imaging, blood tests, or repeated drug administration to manage chronic illness. Drugs will no longer flood the body and cause systemic side effects. They will be produced locally and precisely. We will be sick and cured without even knowing."
Looking Ahead: A Paradigm Shift in Therapeutic Thinking
The next five to ten years hold immense promise for the field of cellular therapeutics, and Dr. Walton is particularly enthusiastic about the potential for this revolutionary concept to become mainstream. "I believe that in the next five to ten years, work from pioneer laboratories like ours will begin to introduce a new idea into mainstream thinking: that the future of medicine lies in a secondary immune system engineered to cure disease," Dr. Walton asserts. The excitement stems not only from the technological advancements but also from the conceptual shift this research represents. "What excites me most is not only building this technology, but watching the concept itself take root. Seeing people realize that living inside the body could be a self-renewing therapeutic system that detects disease and responds automatically will fundamentally change how society thinks about health."
This projected evolution of medicine suggests a future where chronic diseases, once considered progressive and intractable, might become manageable or even reversible through the body’s own intelligently engineered defenses. The National Institutes of Health’s recognition of Dr. Walton’s work with a Transformative Research Award underscores the significant potential and innovative nature of these endeavors. Such awards are designated for research that has the potential to fundamentally change the trajectory of biomedical science and human health. The continued development of smart delivery systems, programmable cells, and a deeper understanding of neurodegenerative processes are expected to accelerate progress in treating a wide range of age-related conditions beyond Alzheimer’s disease, potentially impacting the management of Parkinson’s disease, ALS, and other neurological disorders.
The implications extend beyond individual patient outcomes. A healthcare system less reliant on reactive interventions and expensive, systemically administered drugs could lead to significant cost savings and a more sustainable model for public health. The emphasis on early detection and internal repair aligns with a growing global focus on preventative medicine and personalized healthcare. As Dr. Walton’s research continues to unfold, it offers a compelling vision of a future where aging does not equate to inevitable decline, and where the body’s own cellular machinery can be harnessed to maintain health and combat disease with unprecedented precision and efficacy. The ongoing work at the Buck Institute, spearheaded by scientists like Dr. Chaska Walton, represents a beacon of hope for millions affected by age-related diseases, signaling a future where living better, longer is not just an aspiration, but an achievable reality.
